Cargando…
Bronchopulmonary Penetration of Isavuconazole in Pulmonary Transplant Recipients (PBISA01): Protocol for a Phase IV Clinical Trial With a Single Treatment Arm
BACKGROUND: Aspergillosis is the most frequently observed invasive fungal disease (IFD) in lung transplant recipients. Isavuconazole (ISA) has shown a better safety profile and noninferiority to voriconazole in the treatment of patients with IFD. OBJECTIVE: The aim of this study is to describe the b...
Autores principales: | Darnaude-Ximénez, Ignacio, Caballero-Bermejo, Antonio F, Ruiz-Antorán, Belén, Aguilar-Pérez, Myriam, Gómez-López, Alicia, Sancho-López, Aranzazu, García-Fadul, Cristian, Diago-Sempere, Elena, Valle Falcones, Manuel, Ussetti-Gil, Piedad, Avendaño-Solá, Cristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520388/ https://www.ncbi.nlm.nih.gov/pubmed/36103230 http://dx.doi.org/10.2196/37275 |
Ejemplares similares
-
Bronchopulmonary penetration of isavuconazole in lung transplant recipients
por: Caballero-Bermejo, Antonio F., et al.
Publicado: (2023) -
Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial
por: Caballero Bermejo, Antonio F., et al.
Publicado: (2020) -
Successful Treatment of Allergic Bronchopulmonary Aspergillosis With Isavuconazole: Case Report and Review of the Literature
por: Jacobs, Samantha E., et al.
Publicado: (2017) -
Penetration of Isavuconazole in Ascites Fluid of Critically Ill Patients
por: Lahmer, Tobias, et al.
Publicado: (2021) -
Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial
por: Diago-Sempere, Elena, et al.
Publicado: (2021)